Abbott announced has received marketing authorization from the European Commission for once-daily dosing of the Kaletra (lopinavir/ritonavir) tablet, the company's leading HIV protease inhibitor (PI), in adult patients new to HIV therapy.
The details can be read here.
No comments:
Post a Comment